Floatz logo

Budesonide

Asthma

New York City Health and Hospitals CorporationSmall moleculePhase 4 / ApprovedDormant
BBB
79/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Asthma cohort.

Asset / SponsorPhaseRating
SALMETEROL
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 4BBB
Flixotide
GlaxoSmithKline
Phase 4BBB
Montelukast
Kafrelsheikh University
Phase 4BBB
MK-0476
Organon and Co
Phase 4BB
Mirabegron
Kafrelsheikh University
Phase 4BB

View all 47 →

Same molecule, other indications

Budesonide is also rated in:

childhood acute lymphoblastic leukemiaDormant
B
Indicative · Phase 4
63 / 100
View asset →
primary biliary cholangitisDormant
B
Indicative · Phase 3
60 / 100
View asset →
HER2 positive breast carcinomaDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →